Horizon Pharma Inc. (NASDAQ:HZNP) shot up 2% on Tuesday . The stock traded as high as $20.03 and last traded at $19.26, with a volume of 4,419,438 shares trading hands. The stock had previously closed at $18.89.

Several brokerages have weighed in on HZNP. Vetr upgraded shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating and set a $21.00 target price for the company in a research note on Monday, June 13th. Stifel Nicolaus reiterated a “buy” rating on shares of Horizon Pharma in a research note on Tuesday, April 12th. TheStreet downgraded shares of Horizon Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th. Zacks Investment Research upgraded shares of Horizon Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 11th. Finally, Brean Capital reiterated a “buy” rating on shares of Horizon Pharma in a research note on Tuesday. One analyst has rated the stock with a sell rating, three have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $28.46.

The company has a market capitalization of $3.12 billion and a price-to-earnings ratio of 252.34. The company has a 50 day moving average price of $17.91 and a 200-day moving average price of $16.93.

Horizon Pharma (NASDAQ:HZNP) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.04. The company earned $204.70 million during the quarter, compared to analyst estimates of $197.73 million. The company’s quarterly revenue was up 80.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.18 EPS. Equities analysts forecast that Horizon Pharma Inc. will post $2.35 EPS for the current fiscal year.

In other news, Director Virinder Nohria sold 25,000 shares of the company’s stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $17.69, for a total value of $442,250.00. Following the completion of the transaction, the director now owns 189,836 shares in the company, valued at approximately $3,358,198.84. The sale was disclosed in a document filed with the SEC, which is available at this link.

Several hedge funds and institutional investors recently modified their holdings of HZNP. RS Investment Management Co. LLC boosted its position in shares of Horizon Pharma by 59.8% in the fourth quarter. RS Investment Management Co. LLC now owns 2,210,448 shares of the biopharmaceutical company’s stock valued at $47,900,000 after buying an additional 826,898 shares during the last quarter. Airain ltd acquired a new stake in shares of Horizon Pharma during the fourth quarter worth $2,123,000. Dimensional Fund Advisors LP boosted its stake in shares of Horizon Pharma by 104.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 557,772 shares of the biopharmaceutical company’s stock worth $12,089,000 after buying an additional 284,359 shares in the last quarter. Redwood Investments LLC boosted its stake in shares of Horizon Pharma by 43.8% in the fourth quarter. Redwood Investments LLC now owns 111,682 shares of the biopharmaceutical company’s stock worth $2,420,000 after buying an additional 34,008 shares in the last quarter. Finally, Hodges Capital Management Inc. boosted its stake in shares of Horizon Pharma by 4.1% in the fourth quarter. Hodges Capital Management Inc. now owns 1,571,794 shares of the biopharmaceutical company’s stock worth $34,061,000 after buying an additional 61,454 shares in the last quarter.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.